Shattuck Labs (STTK) Assets Average (2020 - 2026)
Shattuck Labs (STTK) posted quarterly Assets Average of $96.6 million for Q1 2026, up 14.82% year-over-year from $84.1 million in Q1 2025, and up 0.93% quarter-over-quarter from $95.7 million in Q4 2025.
Shattuck Labs (STTK) Assets Average (2020 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Assets Average for 7 consecutive years, with $96.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 14.82% year-over-year to $96.6 million; the TTM figure through Mar 2026 stood at $96.6 million (up 14.82% YoY), while the FY2025 annual figure was $91.0 million, down 27.35% from the prior year.
- Assets Average advanced to $96.6 million in Q1 2026 per STTK's latest filing, from $95.7 million in the prior quarter.
- Across five years, Assets Average topped out at $284.5 million in Q1 2022 and bottomed at $70.8 million in Q2 2025.
- Historically, Assets Average has averaged $152.0 million across 5 years, with a median of $142.9 million in 2023.
- Annual changes were most pronounced in 2025 — Assets Average slumped 48.52% — and 2026, when it gained 14.82%.
- Shattuck Labs' Assets Average stood at $214.1 million in 2022, then plunged by 32.28% to $145.0 million in 2023, then tumbled by 30.08% to $101.4 million in 2024, then slipped by 5.63% to $95.7 million in 2025, then grew by 0.93% to $96.6 million in 2026.
- Business Quant data shows STTK's Assets Average at $96.6 million in Q1 2026, $95.7 million in Q4 2025, and $82.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | 161.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 161.39 Mn |
| Mar 31, 2026 | 96.57 Mn |
| Dec 31, 2025 | 95.68 Mn |
| Sep 30, 2025 | 82.35 Mn |
| Jun 30, 2025 | 70.77 Mn |
| Mar 31, 2025 | 84.11 Mn |
| Dec 31, 2024 | 101.38 Mn |
| Sep 30, 2024 | 120.17 Mn |
| Jun 30, 2024 | 137.47 Mn |
| Mar 31, 2024 | 152.95 Mn |
| Dec 31, 2023 | 145.01 Mn |
| Sep 30, 2023 | 142.86 Mn |
| Jun 30, 2023 | 166.47 Mn |
| Mar 31, 2023 | 191.50 Mn |
| Dec 31, 2022 | 214.13 Mn |
| Sep 30, 2022 | 237.14 Mn |
| Jun 30, 2022 | 260.92 Mn |
| Mar 31, 2022 | 284.54 Mn |
| Dec 31, 2021 | 304.58 Mn |
| Sep 30, 2021 | 317.17 Mn |